GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: BHV-7000 | BHV7000 | example 475 [US20230000831] [1]
Compound class:
Synthetic organic
Comment: Opakalim (BHV-7000) is a selective Kv7.2 and Kv.7.3 channel activator/opener [2] .
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Opakalim (BHV-7000) was progressed as a clinical candidate for the treatment of epilepsy or depressive disorders. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06443463 | Long-term Safety and Tolerability of BHV-7000 | Phase 2 Interventional | Biohaven Pharmaceuticals, Inc. | ||
| NCT06132893 | A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Phase 2/Phase 3 Interventional | Biohaven Pharmaceuticals, Inc. | ||
| NCT06309966 | Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Phase 2/Phase 3 Interventional | Biohaven Pharmaceuticals, Inc. | ||
| NCT06419582 | BHV-7000 Acute Treatment of Bipolar Mania | Phase 2/Phase 3 Interventional | Biohaven Pharmaceuticals, Inc. | ||
| NCT06419608 | Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression | Phase 2 Interventional | Biohaven Pharmaceuticals, Inc. | ||